NCT03689257 (IBDomics) is a clinical trial in Inflammatory Bowel Diseases, sponsored by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa.

What condition does NCT03689257 study?

NCT03689257 studies Inflammatory Bowel Diseases.

Is NCT03689257 still recruiting?

NCT03689257 is currently completed. Last updated 29 July 2020.

Last reviewed 2020-07-29 · How we verify

NCT03689257: IBDomics

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Epidemiology and the Characteristics "Omics" in Patients Recently Diagnosed of Inflammatory Bowel Disease in Spain

Completed Last updated 29 July 2020

What this trial tests

trial in Inflammatory Bowel Diseases in 376 participants. Completed in 1 April 2020.

Timeline

1 October 2017

Primary endpoint
1 April 2020

1 April 2020

Quick facts

Lead sponsor	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Status	Completed
Study type	OBSERVATIONAL
Enrollment	376
Start date	1 October 2017
Primary completion	1 April 2020
Estimated completion	1 April 2020
Sites	16 locations across Spain

Conditions studied

Inflammatory Bowel Diseases — all drugs for Inflammatory Bowel Diseases →

Sponsor

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Who can join

18 and older, any sex, with Inflammatory Bowel Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, observational, multicenter, population-based incidence cohort study which will enroll cases of inflammatory bowel disease IBD (Crohn´s disease CD, ulcerative colitis UC, or indeterminate colitis) diagnosed in adults over 18 months in Spain. In addition, each incident case that gave his/her informed consent, will be followed up for 12 months to determine changes in phenotype or disease location, the need for immunosuppressive and biologic treatments, and the need for hospital admissions and surgery during the first year after diagnosis. Also, samples of of blood, urine and stool will be collected during the first year after diagnosis

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Unveiling the Potential of Extracellular Vesicles as Biomarkers and Therapeutic Nanotools for Gastrointestinal Diseases.
Arrè V, Mastrogiacomo R, Balestra F, Serino G, et al · · 2024 · cited 8× · PMID 38675228 · DOI 10.3390/pharmaceutics16040567

Verify or expand the search:

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

NCT07520747 — A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea · recruiting
NCT07349472 — Pentoxifylline in Patients With Ulcerative Colitis · Phase 2 · recruiting
NCT07033208 — Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance · NA · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06453317 — Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis · Phase 2 · recruiting

Other Fundación de Investigación Biomédica - Hospital Universitario de La Princesa trials

Trials by the same sponsor.

NCT07419230 — Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project · NA · recruiting
NCT07419243 — Tolerance Results and Immune Mechanisms in Cow´s Milk and/or Hen´s Egg Allergic Children Following Natural Evolution or · Phase 1, PHASE2 · recruiting
NCT06450704 — Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders · NA · recruiting
NCT06337565 — Safety of IBD Drugs During Pregnancy and Breasfeeding: Mothers and Babies' Outcomes · recruiting
NCT05927584 — Local Excision for Organ Preservation in Early REctal Cancer With No Adjuvant Treatment · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03689257 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Last refreshed: 29 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03689257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing